Effects of Donepezil or Rivastigmine in Patients with idiopathic REM Sleep Behavior Disorder Patients

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

CRIS

Registry ID

KCT0004317

Enrollment

100

Registered

2019-10-15

Start date

2020-03-02

Completion date

Unknown

Last updated

2019-11-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Drug : product name: Aricept, main ingredient name: Donepezil, dose: 5mg, Dosage form: film coating, pathway: oral, Period: 5 years product name: Exelon, main ingredient name: Rivastigmine, dose:1.5mg

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: -An adult over 50 years old - A person who is confirmed to have REM sleep behavior disorder diagnosis by polysomnography -Those who have no other neurodegenerative diseases

Exclusion criteria

Exclusion criteria: -A patient under 50 years of age. -If you are participating in another clinical trial -A diuretic patient -Women likely to be pregnant -Anyone who has or is taking cocaine. -Anyone who has or is taking a selective serotonin reuptake inhibitor (SSRI) that is likely to develop tricyclic antidepressants and secondary RBDs - Patients with cognitive impairment who understand, agree to conduct, and cannot answer questions correctly -If you have a history of hallucinations or mental illness. -Anyone who had a resistance or side effect on two drugs

Design outcomes

Primary

Measure	Time frame
H & Y stage, Unified Parkinson's disease rating scale (UPDRS)	—

Secondary

Measure	Time frame
REM sleep Behavioral Questionnaire-Korean Version(RBDQ-KR), SCOPA-AUT, K-MMSE, PSQI-K	—

Countries

Korea, Republic of

Contacts

Public ContactSooyeoun You

Keimyung University Dongsan Medical Center

omoi81@hanmail.net+82-53-258-7838

Outcome results